
Nasal Cannula Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Nasal Cannula Market was valued at USD 7.5 billion in 2022 and is poised to grow at a CAGR of over 6.2% from 2023 to 2032. A nasal cannula is a medical device used to deliver supplemental oxygen to individuals that require increased oxygen levels in their bloodstream. It is a lightweight, flexible tube that typically consists of two prongs that are inserted into the nostrils. The other end of the tube is connected to an oxygen source, such as an oxygen cylinders and concentrators.

According to the American Hospital Association, over 34 million patients were admitted to U.S. hospitals for both critical and non-critical procedures in 2022. Consequently, the high rate of hospital admissions is said to drive market growth of cannula throughout the forecast period.
The overall healthcare landscape has witnessed a notable surge in surgical procedures necessitating oxygen support in recent years. There has been a significant increase in the number of surgeries wherein patients require supplemental oxygen. This rise is attributed to several factors, including an aging population base with a higher prevalence of respiratory issues, an increase in complex surgical interventions, and the expanding scope of elective procedures.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2022 |
| Market Size in 2022 | USD 7.5 Billion |
| Forecast Period 2023 to 2032 CAGR | 6.2% |
| Market Size in 2032 | USD 13.5 Billion |
| Key Market Trends | |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
The demand for oxygen support during surgeries underscores the critical importance of ensuring optimal oxygenation for patients undergoing various medical interventions. This trend emphasizes the need for healthcare facilities to adapt and enhance their infrastructure and resources to meet the growing requirements of oxygen-dependent surgical procedures.
The COVID-19 pandemic significantly impacted the nasal cannula market. The surge in respiratory distress cases led to a heightened demand for oxygen delivery devices, with nasal cannulas playing a crucial role. Hospitals faced challenges in managing the influx of patients, leading to strain on resources and disruption in the supply chain. The pandemic prompted a shift toward homecare settings, increasing the need for portable nasal cannulas.
The increasing home healthcare adoption of nasal cannulas reflects a broader trend towards patient-centred care, emphasizing comfort, accessibility, and cost-effectiveness. As technology and healthcare delivery models continue to evolve, the role of nasal cannulas in home-based respiratory care is anticipated to expand further.

The market by type is categorized into low flow and high flow nasal cannula. The low flow nasal cannula segment garnered USD 5.4 billion revenue size in the year 2022.
Moreover, rising awareness, improving healthcare infrastructure, and rising healthcare expenditure further contributes to market expansion.

Based on material, the nasal cannula market is segmented into plastic and silicone. The plastic segment dominated the market and accounted for over 63% business share in the year 2022.
Based on application, the nasal cannula market is segmented into acute respiratory failure, chronic obstructive pulmonary disease (COPD), anesthesia, carbon monoxide toxicity, sleep apnea, acute heart failure, and other applications. The COPD segment accounted for over 27% business share in the year 2022.
Based on end-use, the nasal cannula market is segmented into hospitals, specialty clinics, long-term care centres, ambulatory care centres, homecare settings, and other end-users. The hospitals segment accounted for over 35% revenue share in the year 2022.

U.S. nasal cannula market accounted for over USD 2.9 billion revenue size in 2022 and is predicted to witness substantial market progress.
Moreover, the aging population base in the U.S. has been a significant factor driving the demand for medical devices, including nasal cannulas. As individuals age, there is an increased likelihood of respiratory conditions that may require oxygen therapy.
The nasal cannula industry is fragmented, with key players including Becton, Dickinson and Company and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, the U.S. National Institutes of Health (NIH) and the World Health Organization (WHO) have both recommended the consideration of High-Flow Nasal Cannula (HFNC) therapy, as a viable alternative for delivering respiratory support to specific COVID-19 patients that may not find conventional oxygen therapy to be adequate.
Some of the eminent market participants operating in the nasal cannula industry include:
By Type, 2018 – 2032 (USD Million)
By Material, 2018 – 2032 (USD Million)
By Application, 2018 – 2032 (USD Million)
By End-use, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
Some of the top nasal cannula companies are Salter Labs, Teleflex Incorporated, Becton, Dickinson and Company, Westmed, Inc., Flexicare Medical Limited, Smiths Medical, Medtronic PLC, Sorin Group, and Masimo Corporation.
U.S. nasal cannula market size exceeded USD 2.9 billion in 2022 and is poised to exhibit robust growth rate through 2032 owing to the rising changes in healthcare policies, reimbursement structures, and insurance coverage.
Low flow segment garnered USD 5.4 billion in revenue in 2022 and is estimated to witness high demand through 2032 attributed to widespread usage in chronic conditions, such as chronic obstructive pulmonary disease (COPD) and sleep apnea.
Nasal cannula industry was worth USD 7.5 billion in revenue in 2022 and is projected to reach USD 13.5 billion by 2032 driven by the aging population base with higher prevalence of respiratory issues and the increase in complex surgical interventions.


